Clinical trials
Terminated Phase 2 Glioblastoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 85 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 4 |
| M.D. Anderson Cancer Center | 3 |
| Duke University | 2 |
| Novartis | 2 |
| Novartis Pharmaceuticals | 2 |
| University College, London | 2 |
| University of California, San Francisco | 2 |
| Wake Forest University Health Sciences | 2 |
| Alaunos Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glioblastoma | 85 |
| Glioma | 30 |
| Gliosarcoma | 25 |
| Brain Neoplasms | 24 |
| Astrocytoma | 20 |
| Oligodendroglioma | 11 |
| Central Nervous System Neoplasms | 8 |
| Ependymoma | 3 |
| Recurrence | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.